NFKB1 and neoplasm: MHC-I, TAP1 and B2M expression were found to be up-regulated after treatment of melanoma cells with BO-112, an activator of dsRNA sensing and NF-κB signalling, restoring the cytotoxic activity of tumour-specific T cells [49].